Tags: Drug.
Exenatide (INN marketed as Byetta Bydureon) is a glucagon-like peptide-1 agonist (GLP-1 agonist) medication belonging to the group of incretin mimetics approved in April 2005 for the treatment of diabetes mellitus type 2. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen thigh or arm any time within the 60 minutes before the first and last meal of the day.
